K-Heparin Injection 20000 Units (Heparin Sodium)

Adult administration

Generally administered intravenously or added to the perfusion blood during extracorporeal circulation. Before beginning dialysis, 1,000 to 5,000 IU is administered, followed by a continuous or intermittent additional dose of 500 to 1,500 IU per hour after starting dialysis. Localized heparinization involves continuous administration of 1,500 to 2,500 IU per hour and neutralization with protamine sulfate during internal perfusion.

This medication is very potent and should be used only under the strict supervision of a physician. Caution is especially required for patients with diseases that carry a high risk of bleeding, as bleeding may occur in almost any part of the body during its administration. It should not be used in premature infants, such as underweight babies, as benzyl alcohol contained in this drug can cause life-threatening respiratory issues. It should not be administered to patients with allergies to this drug or its components, abnormal blood coagulation function, existing bleeding, severe liver or kidney diseases, etc. It should also be avoided in patients who have undergone central nervous system surgery or spinal anesthesia. Special care should be taken when administering it to late-pregnancy women, children, the elderly, and patients with specific diseases while closely monitoring their blood coagulation status. Use of this medication may cause bleeding, thrombocytopenia, liver dysfunction, allergic reactions, skin issues, local pain, etc.; any unusual symptoms should be reported to a healthcare professional immediately. Regular blood coagulation tests should be conducted to manage the risk of bleeding, and administration should be stopped or adjusted as needed. If platelet counts drop sharply, this medication should be discontinued immediately, and further tests should be performed. Co-administration with other medications may increase bleeding risk; caution is warranted, especially with aspirin, non-steroidal anti-inflammatory drugs, anticoagulants, etc. Women who are pregnant or breastfeeding should use this medication with caution, considering its effects on the fetus and neonate, particularly regarding the risk of bleeding during childbirth. In cases of overdose, bleeding complications may arise, and the antidote protamine sulfate should be administered immediately, while remaining aware of severe side effects that may arise even when using the antidote. Muscle injections should be avoided due to the risk of hematoma, and this medication should not be mixed with antihistamines for injection.

Serious side effects

Urticaria, angioedema, dyspnea, shock, severe bleeding, acute adrenal insufficiency, adrenal hemorrhage, ovarian hemorrhage, retroperitoneal hemorrhage, thrombocytopenia, arterial and venous thrombosis due to thrombocytopenia, thrombocytopenic syndrome, heparin-induced thrombocytopenia (HIT), heparin-induced thrombocytopenia with thrombosis (HITT)

Mild side effects

Itching, chills, fever, rhinitis, tearing, conjunctivitis, tachycardia, pressure sensation, nausea, vomiting, hypotension, bronchospasm, hair loss, vitiligo, hemorrhagic necrosis, hypoaldosteronism, osteoporosis, rebound effect, dyslipidemia, renal function suppression, localized pain hematoma due to subcutaneous or intramuscular injection, priapism, diabetes, hyperkalemia, hyperaldosteronism, metabolic acidosis, elevation of lipase, vasospastic responses, erythema, mild pain

This medication is sensitive to light, so it should be stored in a tightly sealed container protected from light. The storage temperature should ideally be maintained between 1 degree and 30 degrees Celsius.

Appearance

A transparent liquid ranging from colorless to pale yellow, contained in brown glass vials.

Package unit

20 milliliters × 10 vials